Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Quality of life in cemiplimab-treated patients with locally advanced basal cell carcinoma in a Phase II clinical trial.
Journal: Future oncology (London, England)
Published: July 29, 2024
Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 03, 2023
Real-World Treatment Patterns and Outcomes Among Patients with Basal Cell Carcinoma Following First-Line Hedgehog Inhibitor Discontinuation.
Journal: Dermatology and therapy
Published: December 06, 2021
Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets.
Journal: Nature communications
Published: October 18, 2021
Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.
Journal: The Lancet. Oncology
Published: November 30, 2020
Oncogenic KIT Modulates Type I IFN-Mediated Antitumor Immunity in GIST.
Journal: Cancer immunology research
Published: August 17, 2020
Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial.
Journal: JAMA oncology
Published: January 24, 2020
Misidentification of MLL3 and other mutations in cancer due to highly homologous genomic regions.
Journal: Leukemia & lymphoma
Published: July 11, 2019
Differential immune profiles distinguish the mutational subtypes of gastrointestinal stromal tumor.
Journal: The Journal of clinical investigation
Published: February 15, 2019
Oncogenic kinase inhibition limits Batf3-dependent dendritic cell development and antitumor immunity.
Journal: The Journal of experimental medicine
Published: April 08, 2018
Mitochondrial Inhibition Augments the Efficacy of Imatinib by Resetting the Metabolic Phenotype of Gastrointestinal Stromal Tumor.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 14, 2017
ETV4 collaborates with Wnt/β-catenin signaling to alter cell cycle activity and promote tumor aggressiveness in gastrointestinal stromal tumor.
Journal: Oncotarget
Published: August 30, 2017
Last Updated: 09/26/2026